AnalystsMichelle GilsonMichelle Gilson's Stock Forecasts
AnalystsMichelle Gilson
Sectors:
Analyst Ranking
Bottom 5%
#5040 out of 5266 analysts
Average Return
-31.16%
Win Rate
24%4 out of 17
Risk vs Reward
Poor
Good
Michelle Gilson's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Travere Therapeutics IncTVTX | +50.17% | $14.99 | $22.51 | 2021-05-27 - 2022-05-26 | Strong Buy |
Corcept Therapeutics IncCORT | +24.30% | $19.26 | $23.94 | 2022-02-02 - 2023-02-01 | Strong Buy |
Vir Biotechnology IncVIR | +5.37% | $9.49 | $10.00 | 2026-02-24 - 2026-05-01 | Strong Buy |
Amryt Pharma PLCAMYT | +0.52% | $11.11 | $11.17 | 2020-07-20 - 2021-07-19 | Strong Buy |
Michelle Gilson Analyst Color
Get additional color on Michelle Gilson's coverage of popular stocks
Michelle Gilson's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Vir Biotechnology IncVIR | 5 | Strong Buy | $24.00 | +140.00% | Maintains | 2 months ago |
Q32 Bio IncQTTB | 2 | Strong Buy | $126.00 | N/A | Maintains | 4 years ago |
Corcept Therapeutics IncCORT | 1 | Strong Buy | $30.00 | N/A | Initiates Coverage On | 4 years ago |
Sigilon Therapeutics IncSGTX | 3 | Strong Buy | $91.00 | N/A | Maintains | 4 years ago |
Rezolute IncRZLT | 1 | Strong Buy | $17.00 | N/A | Maintains | 4 years ago |
Ascendis Pharma AASND | 2 | Strong Buy | $196.00 | N/A | Maintains | 5 years ago |
Travere Therapeutics IncTVTX | 1 | Strong Buy | $45.00 | N/A | Maintains | 5 years ago |
Stoke Therapeutics IncSTOK | 1 | Strong Buy | $76.00 | N/A | Maintains | 5 years ago |
Biomarin Pharmaceutical IncBMRN | 4 | Strong Buy | $95.00 | N/A | Maintains | 6 years ago |
Amryt Pharma PLCAMYT | 1 | Strong Buy | $40.00 | N/A | Initiates Coverage On | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.